CSL Limited - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "CSL Limited - Product Pipeline Review - 2014" provides data on the CSL Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, CSL Limited's corporate website, SEC filings, investor presentations and featured press releases, both from CSL Limited and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- CSL Limited - Brief CSL Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of CSL Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of CSL Limited with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the CSL Limited's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate CSL Limited's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of CSL Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the CSL Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with CSL Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of CSL Limited and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
CSL Limited Snapshot 6
CSL Limited Overview 6
Key Information 6
Key Facts 6
CSL Limited - Research and Development Overview 7
Key Therapeutic Areas 7
CSL Limited - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
CSL Limited - Pipeline Products Glance 16
CSL Limited - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
CSL Limited - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
CSL Limited - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
CSL Limited - Drug Profiles 21
C1 esterase inhibitor (human) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CSL-627 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CSL-654 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CSL-112 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CSL-311 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NY-ESO-1 ISCOMATRIX Vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CR-002 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CSL-689 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Oncology Program 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
2H-10 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CSL-324 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CSL-334 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CSL-346 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CSL-650 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Discovery Projects 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Novel Plasma Proteins 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
POD CRC-OHS 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Recombinant Coagulation Factors 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CSL Limited - Pipeline Analysis 43
CSL Limited - Pipeline Products by Therapeutic Class 43
CSL Limited - Pipeline Products by Target 46
CSL Limited - Pipeline Products by Route of Administration 48
CSL Limited - Pipeline Products by Molecule Type 49
CSL Limited - Pipeline Products by Mechanism of Action 50
CSL Limited - Recent Pipeline Updates 52
CSL Limited - Dormant Projects 57
CSL Limited - Company Statement 58
CSL Limited - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
CSL Limited, Key Information 6
CSL Limited, Key Facts 6
CSL Limited - Pipeline by Indication, 2014 9
CSL Limited - Pipeline by Stage of Development, 2014 10
CSL Limited - Monotherapy Products in Pipeline, 2014 11
CSL Limited - Partnered Products in Pipeline, 2014 12
CSL Limited - Partnered Products/ Combination Treatment Modalities, 2014 13
CSL Limited - Out-Licensed Products in Pipeline, 2014 14
CSL Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
CSL Limited - Phase III, 2014 16
CSL Limited - Phase II, 2014 17
CSL Limited - Phase I, 2014 18
CSL Limited - Preclinical, 2014 19
CSL Limited - Discovery, 2014 20
CSL Limited - Pipeline by Therapeutic Class, 2014 44
CSL Limited - Pipeline by Target, 2014 47
CSL Limited - Pipeline by Route of Administration, 2014 48
CSL Limited - Pipeline by Molecule Type, 2014 49
CSL Limited - Pipeline Products by Mechanism of Action, 2014 51
CSL Limited - Recent Pipeline Updates, 2014 52
CSL Limited - Dormant Developmental Projects,2014 57
CSL Limited, Subsidiaries 64